Estrogenic activity of 7-hydroxymatairesinol potassium acetate (HMR/lignan™) from Norway spruce (Picea abies) knots and of its active metabolite enterolactone in MCF-7 cells

Pharmacological Research

Volumn 56, Issue 2, 2007, Pages 140-147

  Cosentino, Marco ^a   Marino, Franca ^a   Ferrari, Marco ^a   Rasini, Emanuela ^a   Bombelli, Raffaella ^a   Luini, Alessandra ^a   Legnaro, Massimiliano ^a   Canne, Marco Gioacchino Delle ^b   Luzzani, Marcello ^b   Crema, Francesca ^c   Paracchini, Silvano ^b   Lecchini, Sergio ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b LINNEA SA   (Switzerland)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

7 Hydroxymatairesinol; Antioxidant; Enterolactone; Estradiol; Health effects; MCF 7 cells

Indexed keywords

7 HYDROXYMATAIRESINOL POTASSIUM ACETATE; ENTEROLACTONE; ESTRADIOL; ESTROGEN RECEPTOR; HMR LIGNAN; LIGNAN DERIVATIVE; MESSENGER RNA; PROTEIN BAX; PROTEIN BCL 2; TAMOXIFEN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CYCLE S PHASE; CELL GROWTH; CELL STRAIN MCF 7; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; ESTROGEN ACTIVITY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; NORWAY SPRUCE; PRIORITY JOURNAL;

4-BUTYROLACTONE; ANTIOXIDANTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIGNANS; PHYTOESTROGENS; PICEA; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, MESSENGER; TAMOXIFEN;

EID: 34548126522     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2007.05.001     Document Type: Article

References (39)

1. Dixon R.A. Phytoestrogens. Annu Rev Plant Biol 55 (2004) 225-261
2. Axelson M., Sjovall J., Gustafsson B.E., and Setchell K.D. Origin of lignans in mammals and identification of a precursor from plants. Nature 298 (1982) 659-660
3. Heinonen S., Nurmi T., Liukkonen K., Poutanen K., Wahala K., Deyama T., et al. In vitro metabolism of plant lignans: new precursors of mammalian lignans enterolactone and enterodiol. J Agric Food Chem 49 (2001) 3178-3186
4. Knight D.C., and Eden J.A. A review of the clinical effects of phytoestrogens. Obstet Gynecol 87 (1996) 897-904
5. Tham D.M., Gardner C.D., and Haskell W.L. Potential health benefits of dietary phytoestrogens: a review of the clinical, epidemiological, and mechanistic evidence. J Clin Endocrinol Metab 83 (1998) 2223-2225
6. Raffaelli B., Hoikkala A., Leppälä E., and Wähälä K. Enterolignans. J Chromatogr B 777 (2002) 29-43
7. Wang L.-Q. Mammalian phytoestrogens: enterodiol and enterolactone. J Chromatogr B 777 (2002) 289-309
8. Cornwell T., Cohick W., and Raskin I. Dietary phytoestrogens and health. Phytochemistry 65 (2004) 995-1016
9. Saarinen N.M., Warri A., Makela S.I., Eckerman C., Reunanen M., Ahotupa M., et al. Hydroxymatairesinol, a novel enterolactone precursor with antitumor properties from coniferous tree (Picea abies). Nutr Cancer 36 (2000) 207-216
10. Willför S., Hemming J., Reunanen M., Eckerman C., and Holmbom B. Lignans and lipophilic extractives in Norway spruce knots and stemwood. Holtzforschung 57 (2003) 27-36
11. Kangas L., Saarinen N., Mutanen M., Ahotupa M., Hirsinummi R., Unkila M., et al. Antioxidant and antitumor effects of hydroxymatairesinol (HM-3000, HMR), a lignan isolated from the knots of spruce. Eur J Cancer Prev 11 Suppl 2 (2002) S48-S57
12. Smeds A.I., Saarinen N.M., Hurmerinta T.T., Penttinen P.E., Sjoholm R.E., and Makela S.I. Urinary excretion of lignans after administration of isolated plant lignans to rats: the effect of single dose and ten-day exposures. J Chromatogr B Analyt Technol Biomed Life Sci 813 (2004) 303-312
13. (Min) mice. Cancer Lett 161 (2000) 253-258
14. Katsuda S., Yoshida M., Saarinen N., Smeds A., Nakae D., Santti R., et al. Chemopreventive effects of hydroxymatairesinol on uterine carcinogenesis in Donryu rats. Exp Biol Med 229 (2004) 417-424
15. Bylund A., Saarinen N., Zhang J.X., Bergh A., Widmark A., Johansson A., et al. Anticancer effects of a plant lignan 7-hydroxymatairesinol on a prostate cancer model in vivo. Exp Biol Med 230 (2005) 217-223
16. Saarinen N.M., Penttinen P.E., Smeds A.I., Hurmerinta T.T., and Makela S.I. Structural determinants of plant lignans for growth of mammary tumors and hormonal responses in vivo. J Steroid Biochem Mol Biol 93 (2005) 209-219
17. Nelson H.D., Humphrey L.L., Nygren P., Teutsch S.M., and Allan J.D. Postmenopausal hormone replacement therapy: scientific review. JAMA 288 (2002) 872-881
18. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., et al. Writing group for the women's health initiative investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA 288 (2002) 321-333
19. Ettinger B., Grady D., Tosteson A.N., Pressman A., and Macer J.L. Effect of the women's health initiative on women's decisions to discontinue postmenopausal hormone therapy. Obstet Gynecol 102 (2003) 1225-1232
20. Buist D.S., Newton K.M., Miglioretti D.L., Beverly K., Connelly M.T., Andrade S., et al. Hormone therapy prescribing patterns in the United States. Obstet Gynecol 104 (2004) 1042-1050
21. Hersh A.L., Stefanick M.L., and Stafford R.S. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 291 (2004) 47-53
22. Ettinger B., Barrett-Connor E., Hoq L.A., Vader J.P., and Dubois R.W. When is it appropriate to prescribe postmenopausal hormone therapy?. Menopause 13 (2006) 404-410
23. Ma J., Drieling R., and Stafford R.S. US women desire greater professional guidance on hormone and alternative therapies for menopause symptom management. Menopause 13 (2006) 506-516
24. Re R., Pellegrini N., Proteggente A., Pannala A., Yang M., and Rice-Evans C. Antioxidant activity applying an improved ABTS radical cation decolorization assay. Free Rad Biol Med 26 (1999) 1231-1237
25. Bondet V., Brand-Williams W., and Berset C. Kinetics and mechanisms of antioxidant activity using the DPPH free radical method. Lebensm-Wiss u Technol 30 (1997) 609-615
26. Parejo I., Codina C., Petrakis C., and Kefalas P. Evaluation of scavenging activity assessed by Co(II)/EDTA-induced luminol chemiluminescence and DPPH* (2,2-diphenyl-1-picrylhydrazyl) free radical assay. J Pharmacol Toxicol Meth 44 (2000) 501-512
27. Choi C.W., Kim S.C., Hwang S.S., Choi B.K., Ahn H.J., Lee M.Y., et al. Antioxidant activity and free radical scavenging capacity between Korean medicinal plants and flavonoids by assay-guided comparison. Plant Sci 163 (2002) 1161-1168
28. Gotz M.E., Dirr A., Freyberger A., Burger R., and Riederer P. The thiobarbituric acid assay reflects susceptibility to oxygen induced lipid peroxidation in vitro rather than levels of lipid hydroperoxides in vivo: a methodological approach. Neurochem Int 22 (1993) 255-262
29. Chan S.L., and Yu V.C. Proteins of the Bcl-2 family in apoptosis signalling: from mechanistic insights to therapeutic opportunities. Clin Exp Pharmacol Physiol 31 (2004) 119-128
30. Antonsson B. Bax and other pro-apoptotic Bcl-2 family "killer-proteins" and their victim the mitochondrion. Cell Tissue Res 306 (2001) 347-361
31. Kim R. Unknotting the roles of Bcl-2 and Bcl-xL in cell death. Biochem Biophys Res Commun 333 (2005) 336-343
32. Mousavi Y., and Adlercreutz H. Enterolactone and estradiol inhibit each other's proliferative effect on MCF-7 breast cancer cells in culture. J Steroid Biochem Mol Biol 41 (1992) 615-619
33. Wang C., and Kurzer M.S. Phytoestrogen concentration determines effects on DNA synthesis in human breast cancer cells. Nutr Cancer 28 (1997) 236-247
34. Lina B., Korte H., Nyman L., and Unkila M. A thirteen week dietary toxicity study with 7-hydroxymatairesinol potassium acetate (HMR lignan) in rats. Regul Toxicol Pharmacol 41 (2005) 28-38
35. Riggs B.L., and Hartmann L.C. Selective estrogen-receptor modulators-mechanisms of action and application to clinical practice. N Engl J Med 348 (2003) 618-629
36. Kilkkinen A., Stumpf K., Pietinen P., Valsta L.M., Tapanainen H., and Adlercreutz H. Determinants of serum enterolactone concentration. Am J Clin Nutr 73 (2001) 1094-1100
37. Hormos Nutraceutical Oy Ltd. Tolerability safety and kinetics of hydroxymatairesinol (HMRLignan™), a nutraceutical product, and its effects on lipoprotein oxidation products after multiple dosing. Clinical study report no. 3000-5201; 2004.
38. Scheuermann R.H., and Bauer S.R. Polymerase chain reaction-based mRNA quantification using an internal standard: analysis of oncogene expression. Meth Enzymol 218 (1993) 446-473
39. Zhou H.B., Chen J.J., Wang W.X., Cai J.T., and Du Q. Anticancer activity of resveratrol on implanted human primary gastric carcinoma cells in nude mice. World J Gastroenterol 11 (2005) 280-284